NCT02392208View on ClinicalTrials.gov

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
End-Stage Renal DiseaseStage 5 Chronic Kidney Disease
Interventions
DRUG

Telavancin

A single 5 mg/kg dose of telavancin is administered intravenously (IV).

PROCEDURE

Pharmacokinetic Blood Sampling

Blood samples are collected to assess telavancin plasma concentrations.

Trial Locations (1)

48109

University of Michigan Hospital, Ann Arbor

Sponsors

Collaborators (1)

Theravance Biopharma
All Listed Sponsors
collaborator

Theravance Biopharma

INDUSTRY

lead

University of Michigan

OTHER